LATAM MedTech Insights

Last week, Brazil's regulatory agency, ANVISA, issued an unexpected technical guidance that reclassifies certain Software as a Medical Device (SaMD) products. This move has sent shockwaves through the digital health sector, pushing many devices that rely on predictive algorithms into higher-risk categories overnight, invalidating existing registrations.

In this episode of LATAM MedTech Insights, we break down what this clarification means for manufacturers, the new clinical evidence required for compliance under RDC 751, and why this signals a major strategic shift in Brazil's approach to digital health regulation. We explore the immediate commercial impact and the long-term strategic adjustments companies must now consider.

Case in Point: Imagine your popular diabetes management app was approved as a Class II device. Suddenly, ANVISA's new interpretation of its predictive algorithm makes it a Class III product. Your registration is now invalid, marketing must cease, and you face the monumental task of generating local clinical data for a completely new submission. This is the exact challenge facing companies in Brazil right now.

This episode's key questions:
- How can a simple "technical guidance" invalidate your existing product registration in Brazil?
- What specific software functions are now considered high-risk by ANVISA?
- Is your current technical dossier prepared for this new level of scrutiny?
- Why is relying on your existing EU or FDA clearance no longer enough for the Brazilian market?
- What are the immediate steps you must take if your SaMD product is affected?
- How does this change impact the market entry strategy for new digital health products in LATAM?
- Could this regulatory pattern be replicated in other key LATAM markets?

Feeling overwhelmed by the shifting regulatory landscape? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies. We combine local expertise in over 30 markets, including Brazil, with advanced AI tools to streamline global market access and ensure you stay compliant. Don't let regulatory surprises derail your strategy. Contact us for a consultation at [email protected] or visit https://pureglobal.com/.

This week on LATAM MedTech Insights, we dive into the significant new regulatory guidance from Brazil's ANVISA that is reshaping the landscape for Software as a Medical Device (SaMD). This update brings Brazil closer to global standards but introduces critical new challenges for foreign manufacturers in areas like risk classification, AI validation, and cybersecurity.

We explore the immediate impact on MedTech companies aiming for the Brazilian market. For example, a US-based digital health firm was on the verge of submitting its product for approval. Now, they're confronting the painful reality that their AI algorithm's validation data is insufficient under the new, stricter guidelines, forcing them into a costly and time-consuming redevelopment cycle just to meet compliance. This episode unpacks how to anticipate and navigate these exact scenarios.

Key Takeaways:
- What are the three most critical changes in ANVISA's new SaMD framework?
- How will the new risk classifications impact your product's path to market?
- Are your cybersecurity measures compliant with both ANVISA's new rules and Brazil's LGPD?
- What new clinical evidence is required for AI and machine learning-driven SaMD?
- How can you leverage your existing international dossiers for the new submission process?
- Why might your previous go-to-market strategy for Brazil now be obsolete?
- What is the single biggest mistake companies make when interpreting new ANVISA guidance?

Navigating evolving regulatory landscapes is our expertise. Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, using local experts and advanced AI tools to streamline market access in over 30 countries, including Brazil. From regulatory strategy and dossier submission to acting as your local in-country representative, we turn complexity into clarity. Don't let regulatory hurdles derail your expansion. Contact us at [email protected] or visit https://pureglobal.com to learn more.

This week, we dive into a major regulatory shift in Brazil that just went live on March 1st, 2026. ANVISA's new Normative Instruction N°426/2026 activates the national UDI (Unique Device Identification) database, requiring manufacturers to submit detailed product data before entering the market. This episode breaks down the new requirements, the critical phased deadlines for different device classes, and the strategic implications for MedTech companies aiming to succeed in Latin America's largest market.

We explore the hidden complexities, such as the absolute need for data equivalence between your ANVISA registration and your UDI submission. Consider the case of a cardiac stent manufacturer whose multi-million dollar product launch is completely stalled because of a single data mismatch in the new system. This highlights how a small administrative detail can become a major commercial barrier.

Key Questions for This Episode:
- Brazil's new UDI system just went live; are you prepared for the aggressive, risk-based deadlines?
- What are the most common data mismatches that can block your market access?
- Should you manage complex UDI submissions in-house or delegate them to a local Brazilian partner?
- How does ANVISA's new database compare to the UDI systems in the US and Europe?
- What is the single most critical step to take before submitting your first UDI record to ANVISA?
- Are your current data management systems robust enough for this new era of traceability?
- How can you leverage your Brazil Registration Holder to streamline this new compliance burden?

At Pure Global, we specialize in turning these regulatory challenges into market opportunities. With our deep local expertise in Brazil and advanced AI-driven data tools, we provide end-to-end regulatory consulting to ensure your market access is seamless and compliant. We act as your local representative, manage technical dossier submissions, and navigate complex requirements like the new UDI system. To streamline your entry into Brazil and over 30 other global markets, contact us at [email protected] or visit https://pureglobal.com/.

This episode of LATAM MedTech Insights, brought to you by Pure Global, dives into the landmark regulatory shift just implemented by Brazil's ANVISA. We unpack the new RDC 830/2023 resolution for In-Vitro Diagnostic (IVD) devices, a critical update that redefines market access and compliance in Latin America's largest market.

We explore how this harmonization with global standards impacts everything from risk classification to technical documentation. More importantly, we reveal the new strategic 'reliance pathway' that could dramatically accelerate your product's journey to market. Imagine your high-risk diagnostic device, facing a potential year-long review, suddenly becoming eligible for an expedited process in just a few months. This is now a reality for companies with existing approvals from major global authorities, but only if you know how to navigate the new system.

Key questions answered in this episode:
- What are the specific changes in ANVISA's new RDC 830/2023 for IVDs?
- How do I determine if my IVD product's risk class has changed in Brazil?
- What is the new 'reliance pathway' and which country approvals make me eligible?
- How can leveraging my FDA or Health Canada approval cut my Brazilian registration time by over 70%?
- What are the immediate steps my company must take to ensure compliance and avoid market access delays?
- Does this change make Brazil a more attractive or more difficult market for IVD manufacturers?

At Pure Global, we specialize in turning these complex regulatory updates into clear, actionable strategies. With local experts in Brazil and advanced AI tools, we manage the entire registration lifecycle, helping you leverage new pathways to gain a competitive edge. To ensure your company is prepared for the new era of IVD regulation in Brazil, contact us at [email protected] or visit https://pureglobal.com/.

A seismic regulatory shift is underway in Brazil, Latin America's biggest MedTech market. ANVISA's new Unique Device Identification (UDI) system, detailed in Normative Instruction 426/2026, is now being implemented. This isn't just a new labeling rule; it's a complex data management and submission challenge that could become a major barrier to market entry for unprepared device manufacturers.

This episode breaks down exactly what the new requirements mean for your business. We go beyond the surface-level announcements to explore the practical, operational hurdles you will face. We discuss the critical importance of the SIUD database, the staggered compliance deadlines for different device classes, and why your existing global UDI strategy might not be enough for Brazil.

Consider this: A successful European device company planned a major launch in Brazil, only to be halted for six months. The reason was not their product's quality, but their inability to provide the specific data attributes required by the new SIUD database, a detail they completely overlooked. This episode is designed to help you avoid that costly mistake.

Key Takeaways:
* What is Brazil's Normative Instruction 426/2026, and why is it a game-changer for market access?
* How does the new SIUD database fundamentally alter device traceability requirements?
* Are your data management systems prepared for the specific submission formats ANVISA demands?
* What are the staggered compliance deadlines, and which one applies to your device portfolio?
* Why is simply having a UDI on your label completely insufficient for the Brazilian market?
* How can this regulatory hurdle be turned into a competitive advantage against slower rivals?
* What are the most common pitfalls foreign manufacturers face when dealing with ANVISA's new rules?

At Pure Global, we specialize in navigating these complexities. We provide end-to-end regulatory consulting, acting as your local representative and using advanced AI tools to ensure your technical dossiers are compliant and submitted efficiently. Don't let regulatory hurdles derail your expansion. Contact us at [email protected] or visit https://pureglobal.com/.